Our Company
Homeoproteins platform as disease modying therapies

BrainEver has been co-founded by Bernard Gilly (iBionext Network), Alain Prochiantz (Collège de France, Paris, France) and others in March 2015.

BrainEver innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including epigenetic stability and metabolism.

BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.

Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease.

Management

BERNARD GILLY

Founder and Chief Executive Officer

Alain Prochiantz

ALAIN PROCHIANTZ

Founder and Chief Scientific Officer

ANNE BOUSSEAU

Chief Medical Officer

Board of Directors

BERNARD GILLY

Chairman

ALEXIA PEROUSE

Director, Representative of iBionext Growth Fund participations

CHAHRA LOUAFI

Director, Representative of Bpifrance Investissement participations

BERVIN BOUANI

Observer, Representative of Turenne Capital participations

Scientific Advisors

NITZA THOMASSON

Scientific Advisor

Stephane Palfi

STEPHANE PALFI

Medical Advisor

Corvole

JEAN CHRISTOPHE CORVOL

Medical Advisor

JEFFREY KORDOWER

Scientific Advisor

TAKAO HENSCH

Scientific Advisor

Investors
ibionext

iBionext Growth Fund is the first entrepreneurial fund with the knowledge and capacity to build leading companies in 4-5 years while covering the full financing chain of innovation to maximize value from creation to growth.

bpifrance

Bpifrance, a subsidiary of the Caisse des Dépôts and the French State, a trusted partner for entrepreneurs, supports companies from start-up to their listing on the stock market, through credit, guarantees and equity.

turenne

Turenne Capital is an independent private equity firm  with € 700 million under management or advised, including € 120 million in Healthcare.